Patents by Inventor Jasbir S. Seehra

Jasbir S. Seehra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12269858
    Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.
    Type: Grant
    Filed: January 9, 2024
    Date of Patent: April 8, 2025
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Publication number: 20250034148
    Abstract: The invention relates to methods of treating functional iron deficiency (FID) associated with low, very low, or intermediate risk myelodysplastic syndromes. FID associated with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF), and FID associated with myelodysplastic syndromes/myeloproliferative neoplasm (MPN) overlap syndromes using small molecule ALK2 inhibitors.
    Type: Application
    Filed: November 2, 2022
    Publication date: January 30, 2025
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Christopher R. ROVALDI, Elissa FURUTANI
  • Publication number: 20240252631
    Abstract: The invention features methods of treating a subject receiving a cytopenia-associated myelofibrosis treatment by co-administering an activin receptor type II (ActRII) signaling inhibitor. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.
    Type: Application
    Filed: February 16, 2024
    Publication date: August 1, 2024
    Inventors: Jasbir S. SEEHRA, Jennifer Lachey, Christopher R. Rovaldi, Elissa Furutani
  • Publication number: 20240228583
    Abstract: The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and/or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 11, 2024
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Claire TSENG, Elissa FURUTANI, Christopher R. ROVALDI
  • Publication number: 20240218061
    Abstract: The invention features methods of treating a subject having a cytopenia associated with a myelodysplastic syndrome, a cytopenia associated with chronic myelomonocytic leukemia, or a cytopenia associated with myelofibrosis, such as anemia, thrombocytopenia, or neutropenia, by administering to the subject an ActRII signaling inhibitor, such as an ActRIIA ligand trap including an extracellular ActRIIA variant. The extracellular ActRIIA variant may be fused to an Fc domain or moiety.
    Type: Application
    Filed: December 20, 2023
    Publication date: July 4, 2024
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Christopher R. ROVALDI, Elissa FURUTANI
  • Publication number: 20240209048
    Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Application
    Filed: February 16, 2024
    Publication date: June 27, 2024
    Inventors: Jasbir S. SEEHRA, Jennifer Lachey
  • Publication number: 20240141012
    Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY
  • Patent number: 11912750
    Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 27, 2024
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Publication number: 20240050528
    Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 15, 2024
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY
  • Patent number: 11884715
    Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 30, 2024
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Publication number: 20230406956
    Abstract: The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors. The invention also features methods of decreasing iron levels in a subject by administering BMP or hepcidin inhibitors.
    Type: Application
    Filed: April 27, 2023
    Publication date: December 21, 2023
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Christopher R. ROVALDI, Claudia ORDONEZ
  • Publication number: 20230398118
    Abstract: The invention features methods of treating or preventing the development of a cardiovascular-related disease by administering to the subject a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor.
    Type: Application
    Filed: April 26, 2023
    Publication date: December 14, 2023
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Claudia ORDONEZ, Christopher R. ROVALDI
  • Publication number: 20230372390
    Abstract: The invention features methods of treating or preventing lymphopenia in a subject treated with a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor, by co-administering an iron supplement with the inhibitor, and methods of treating a subject who has or is at risk of developing a disease or condition that can be treated with a BMP inhibitor or a hepcidin inhibitor, such as an ALK2 inhibitor, by administering to the subject a BMP inhibitor or a hepcidin inhibitor and an iron supplement.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 23, 2023
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Christopher R. ROVALDI, Claudia ORDONEZ
  • Publication number: 20230348565
    Abstract: The invention features polypeptides that include an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.
    Type: Application
    Filed: March 30, 2023
    Publication date: November 2, 2023
    Inventors: Jasbir S. SEEHRA, Christopher R. ROVALDI
  • Publication number: 20230265162
    Abstract: The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and age-related and treatment-related metabolic disease.
    Type: Application
    Filed: September 15, 2022
    Publication date: August 24, 2023
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Elissa FURUTANI
  • Patent number: 11717558
    Abstract: The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: August 8, 2023
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Publication number: 20230087128
    Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.
    Type: Application
    Filed: September 15, 2022
    Publication date: March 23, 2023
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Elissa FURUTANI
  • Publication number: 20230079602
    Abstract: The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and/or pulmonary hypertension.
    Type: Application
    Filed: September 15, 2022
    Publication date: March 16, 2023
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Claire TSENG, Jason O'NEILL, Henning THØGERSEN, Elissa FURUTANI
  • Publication number: 20220401445
    Abstract: The invention relates to methods of treating multiple osteochondroma and anemia resulting from iron imbalance using small molecule ALK2 inhibitors.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 22, 2022
    Inventors: Jasbir S. SEEHRA, Jennifer LACHEY, Elissa FURUTANI
  • Patent number: 11484573
    Abstract: The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving bone damage, e.g., primary osteoporosis, secondary osteoporosis, osteopenia, osteopetrosis, fracture, bone cancer or cancer metastasis-related bone loss, Paget's disease, renal osteodystrophy, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: November 1, 2022
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jennifer Lachey, Jasbir S. Seehra